Initiating Coverage. BioSig Technologies, Inc. is commercializing a proprietary high-fidelity, low noise cardiac signal processing platform that we believe is a game-changing technology. Somewhat like viewing high-definition TVs vs. standard-definition sets, the PURE EP System, compared to current platforms, provides electrophysiologists (EPs) with advanced signal clarity during electrophysiology ablation procedures that target heart electrical signal misfires. We are initiating coverage with an Outperform rating and a $4.00 one-year price target.Target market is high revenue electrophysiology arrhythmia procedures. Arrhythmias are a growing healthcare concern and ablation procedures to alleviate the problem are improving the situation. The PURE EP System, by improving clinical outcomes, can advance ablation as the standard of care. While PURE EP currently has FDA clearance, the company is also seeking to obtain CE Mark, expanding the market opportunity further.There’s more to BioSig’s technology. BioSig Technologies also expects to leverage their patented signal capture technology in additional bioelectronic applications. NeuroClear is a BioSig subsidiary seeking to use the technology to address autonomic (involuntary, without conscious control) nervous system disorders using N-SENSE, a novel platform for high-speed electroneurogram (ENG) recordings. Pandemic has impacted product evaluation and sales results to date, but we see better uptake coming. As the world progresses past the Covid pandemic, and given the company’s re-focused commercialization efforts, we see an improving market in 2022 and beyond. Price Target $4.00. We believe BSGM valuation to be driven by PURE EP revenue growth and, ultimately, earnings growth. Commercialization efforts underway will advance PURE EP as a desirable, if not "must-have" component of electrophysiology labs in the U.S. and abroad. We are initiating coverage of BioSig Technologies, Inc. with an Outperform rating and a one-year $4.00 target. Our target is based on expected $0.53 2027 EPs, discounted 20% and applying a 20x multiple. Read More >>